Compare Robinhood Markets, Inc. (HOOD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Robinhood Markets, Inc. trades at $109.02 (market cap $96.21B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Robinhood Markets, Inc. is far larger — about 45× Recursion Pharmaceuticals Inc's market cap, and Robinhood Markets, Inc. is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| HOOD | RXRX | |
|---|---|---|
Market Cap | $96.21B | $2.14B |
Volume | 22,572,153 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $147.08 | $6.79 |
52-Week Low | $65.16 | $2.84 |
Typical Hold Time | 75 Days | 23 Days |
Enterprise Value | $102.75B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $107.01, down 2.28% today, as the stock consolidates near pivot point support at $107. The company shows strong fundamental momentum with revenue growing from $3.0B in 2024 to $4.5B in 2025 and net income reaching $1.88B. Recent announcements include plans for 24/7 stock trading and expanded product offerings, positioning the company for continued growth in the expanding e-brokerage market.
HOOD presents a compelling growth story with robust profitability metrics and analyst optimism, though elevated valuation ratios and execution risks warrant caution. The stock's technical setup suggests near-term consolidation with upside potential toward the $137.53 consensus price target, supported by strong institutional sentiment and innovative business initiatives.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
